Illumina forecasts 2026 EPS of $5.40-$5.45 while raising revenue outlook to $4.64B-$4.66B (NASDAQ:ILMN)

Illumina raised its 2026 revenue outlook to $4.64B-$4.66B and forecasted 2026 EPS of $5.40-$5.45. The company's updated guidance reflects its expectations for future performance.

Original reporting
Published Oct 29, 2026, 11:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Illumina forecasts 2026 EPS of $5.40-$5.45 while raising revenue outlook to $4.64B-$4.66B (NASDAQ:ILMN) — source image
Decision brief

The 30-second read

$ILMNBullishMed
01

Why it matters

The guidance raise updates the forward expectation baseline for 2026 profitability and top-line growth, which can influence valuation multiples and positioning ahead of subsequent quarterly updates.

02

Market read

A guidance update with explicit 2026 EPS and revenue ranges is actionable for traders managing forward expectation risk in ILMN.

03

What to watch

Traders may discount guidance if it reflects one-time items, FX assumptions, or timing shifts in customer purchasing cycles that are not described in the scraped text.

Relevance 8/10Novelty 6/10Timing: after-hours guidance update reported for Oct 29, 2026

Background

The piece is an AI-generated earnings-call style summary that reports Illumina’s updated 2026 EPS and revenue outlook.

Company-level read

Ticker impact

$ILMNBullishMedium confidence
Context

Illumina forecasts 2026 EPS of $5.40-$5.45 and raises revenue outlook to $4.64B-$4.66B, signaling updated guidance for the company.

Expected impact

Likely upward bias as the market reprices expectations around the raised 2026 revenue and EPS range.

Evidence & confidence

The article’s only concrete, company-specific content is the guidance update (higher revenue outlook and EPS range), which typically drives expectation revisions even without additional operational detail.

Market effects

Guidance strength from a major genomics tools supplier can modestly improve sentiment toward biotech tools and sequencing-adjacent demand expectations.

Limited direct regional spillover beyond US-listed biotech tools sentiment.

Primarily affects global genomics-instrument and sequencing workflow sentiment rather than broad macro.

Counterpoint

Without details on drivers (pricing, volume, mix, or cost), the market may treat the raise as incremental and focus on whether the new ranges still lag underlying demand.

Key entities

  • Illumina, Inc.

    Provides updated 2026 EPS and revenue guidance ranges in the article.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.